

more information on the proposed project, contact: The Office of Autism Research Coordination, NIMH, NIH, Neuroscience Center, 6001 Executive Blvd., MSC 9663, Room 6184, Bethesda, MD 20892 or Email your request, including your address to: [iaccpublicinquiries@mail.nih.gov](mailto:iaccpublicinquiries@mail.nih.gov). Formal requests for additional plans and instruments must be requested in writing.

**Comment Due Date:** Comments regarding this information collection are best assured of having their full effect if received within 60 days of the date of this publication.

**Proposed Collection:** Autism Spectrum Disorder (ASD) Research Portfolio Analysis, 0925—NEW—National Institute of Mental Health (NIMH), National Institutes of Health (NIH).

**Need and Use of Information Collection:** The purpose of the ASD portfolio analysis is to collect research funding data from U.S. and international ASD research funders, to assist the Interagency Autism Coordinating Committee (IACC) in fulfilling the requirements of the Combating Autism Act, and to inform the committee and interested

stakeholders of the funding landscape and current directions for ASD research. Specifically, these analyses will examine the extent to which current funding and research topics align with the *IACC Strategic Plan for ASD Research*. The findings will help guide future funding priorities by outlining current gaps and opportunities in ASD research as well as serving to highlight annual activities and research progress.

OMB approval is requested for three years. There are no costs to respondents other than their time. The total estimated annualized burden hours are 419.

#### ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondents (funders)	Number of respondents	Number of response per respondent	Average Time per Response (in hours)	Total burden hours
U.S. Federal .....	26	36	15/60	234
U.S. Private .....	12	54	15/60	162
International Government .....	4	14	15/60	14
International Private .....	4	9	15/60	9

Dated: March 26, 2013.

**Sue Murrin,**

*Executive Officer, NIMH, NIH.*

[FR Doc. 2013-12420 Filed 5-23-13; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Cancer Institute; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications/contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

**Name of Committee:** National Cancer Institute Special Emphasis Panel, AIDS and Cancer Specimen Resource (ACSR)

**Date:** May 29, 2013

**Time:** 12:00 p.m. to 5:00 p.m.

**Agenda:** To review and evaluate grant applications

**Place:** National Cancer Institute Shady Grove, Shady Grove, 9609 Medical Center Drive, Room 1E030, Rockville, MD 20850 (Telephone Conference Call)

**Contact Person:** Donald L Coppock, Ph.D., Scientific Review Officer, Special Review and Logistics Branch, Division of Extramural Activities, National Cancer Institute, Shady Grove—NIH, 9609 Medical Center Drive, Room 7W260, Bethesda, MD 20892, 240-276-6382, [donald.coppock@nih.gov](mailto:donald.coppock@nih.gov)

This notice is being published less than 15 days prior to the meeting date due to scheduling conflicts.

**Name of Committee:** National Cancer Institute Special Emphasis Panel, NCI Program Project Meeting II

**Date:** June 12-13, 2013

**Time:** 8:00 a.m. to 5:00 p.m.

**Agenda:** To review and evaluate grant applications

**Place:** Hilton, Rockville, 1750 Rockville Pike, Rockville, MD 20852

**Contact Person:** Majed M. Hamawy, Ph.D., Scientific Review Officer, Research Programs Review Branch, Division Of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W120, Bethesda, MD 20892, 240-276-6457, [mh101v@nih.gov](mailto:mh101v@nih.gov)

**Name of Committee:** National Cancer Institute Special Emphasis Panel, Innovative Technologies for Cancer Biospecimen Science

**Date:** June 12, 2013

**Time:** 12:00 p.m. to 5:00 p.m.

**Agenda:** To review and evaluate grant applications

**Place:** National Cancer Institute—Shady Grove, Shady Grove, 9609 Medical Center Drive, Room 1E030, Rockville, MD 20850 (Telephone Conference Call)

**Contact Person:** Donald L Coppock, Ph.D., Scientific Review Officer, Special Review

and Logistics Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W260, Bethesda, MD 20892, 240-276-6382, [donald.coppock@nih.gov](mailto:donald.coppock@nih.gov)

**Name of Committee:** National Cancer Institute Special Emphasis Panel, RNA Biosensor

**Date:** June 13, 2013

**Time:** 1:00 p.m. to 3:00 p.m.

**Agenda:** To review and evaluate contract proposals

**Place:** National Cancer Institute Shady Grove, Shady Grove, 9609 Medical Center Drive, Room 6W034, Rockville, MD 20850 (Telephone Conference Call)

**Contact Person:** Bratin K. Saha, Ph.D., Scientific Review Officer, Program Coordination and Referral Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W556, Bethesda, MD 20892, 240-276-6411, [sahab@mail.nih.gov](mailto:sahab@mail.nih.gov)

**Name of Committee:** National Cancer Institute Special Emphasis Panel, R13 Review Teleconference

**Date:** June 25, 2013

**Time:** 1:00 p.m. to 5:00 p.m.

**Agenda:** To review and evaluate grant applications.

**Place:** National Cancer Institute Shady Grove, Shady Grove, 9609 Medical Center Drive, Room 6W034, Rockville, MD 20850 (Telephone Conference Call)

**Contact Person:** Bratin K. Saha, Ph.D., Scientific Review Officer, Program Coordination and Referral Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W556, Bethesda, MD 20892, 240-276-6411, [sahab@mail.nih.gov](mailto:sahab@mail.nih.gov)

**Name of Committee:** National Cancer Institute Special Emphasis Panel, NCI Omnibus Biology

**Date:** July 15-16, 2013

Time: 8:00 a.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Place: Doubletree Hotel Bethesda, (Formerly Holiday Inn Select), 8120 Wisconsin Avenue, Bethesda, MD 20814

Contact Person: Zhiqiang Zou, MD, Ph.D., Scientific Review Officer, Special Review and Logistics Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, 7W242, Bethesda, MD 20892, 240-276-6372, [zouzhiq@mail.nih.gov](mailto:zouzhiq@mail.nih.gov)

Information is also available on the Institute's/Center's home page: <http://deainfo.nci.nih.gov/advisory/sep/sep.htm>, where an agenda and any additional information for the meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: May 20, 2013.

**Melanie J. Gray,**

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2013-12377 Filed 5-23-13; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Cancer Institute: Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the National Cancer Institute Special Emphasis Panel, June 20, 2013, 03:00 p.m. to June 21, 2013, 06:00 p.m., Hilton Washington/Rockville, 1750 Rockville Pike, Rockville, MD 20852 which was published in the **Federal Register** on May 06, 2013, 78FR10574.

This notice is being amended due to a change in the meeting date and time from 3:00 p.m. to 6:00 p.m. on June 20 to 21, 2013 to 8:00 a.m. to 5:00 p.m. on June 20, 2013. The meeting is closed to the public.

Dated: May 20, 2013.

**Melanie J. Gray,**

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2013-12376 Filed 5-23-13; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Prospective Grant of a Start-Up Exclusive Patent License Agreement: Treatment of Graves' Disease, Hyperthyroidism and Thyroid Cancer

**AGENCY:** National Institutes of Health, HHS.

**ACTION:** Notice.

**SUMMARY:** This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of a Start-Up Exclusive Patent License to Nova Therapeutics LLC, a company having a place of business in Delaware, to practice the inventions embodied in the following patent applications:

1. PCT Application No.: PCT/US2011/031752 filed 08 Apr 2011, HHS Ref. No.: E-067-2010/0-PCT-02, Titled: Inverse Agonists and Neutral Antagonists for the TSH Receptor, Inventors: Marvin Gershengorn (NIDDK), Susanne Neumann (NIDDK), Wenwei Huang (NCATS), Craig Thomas (NCATS).
2. Australian Application No.: 2011237421 filed 15 Aug 2012, HHS Ref. No.: E-067-2010/0-AU-03.
3. Canadian Application No.: 2,789,818 filed 15 Aug 2012, HHS Ref. No.: E-067-2010/0-CA-04.
4. Chinese Application No.: 201180013235.9 filed 15 Aug 2012, HHS Ref. No.: E-067-2010/0-CN-05.
5. European Application No.: 11766807.9 filed 15 Aug 2012, HHS Ref. No.: E-067-2010/0-EP-06.
6. Indian Application No.: 2055/KOLNP/2012 filed 15 Aug 2012, HHS Ref. No.: E-067-2010/0-IN-07.
7. Japanese Application No.: 2013-503984 filed 15 Aug 2012, HHS Ref. No.: E-067-2010/0-JP-08.
8. U.S. Application No.: 13/579,251 filed 15 Aug 2012, HHS Ref. No.: E-067-2010/0-US-09.

The patent rights in this invention have been assigned to the Government of the United States of America. The territory of the prospective Start-Up Exclusive Patent License Agreement may be worldwide and the field of use may be limited to: Treatment of Graves' Disease, hyperthyroidism and thyroid cancer.

**DATES:** Only written comments or applications for a license (or both) which are received by the NIH Office of Technology Transfer on or before June 10, 2013 will be considered.

**ADDRESSES:** Requests for copies of the patent application, inquiries, comments, and other materials relating to the

contemplated Start-Up Exclusive Patent License Agreement should be directed to: Lauren Nguyen-Antczak, Ph.D., Licensing and Patenting Manager, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3804; Telephone: (301) 435-4074; Facsimile: (301) 402-0220; Email: [Lauren.Nguyen-antczak@nih.gov](mailto:Lauren.Nguyen-antczak@nih.gov). A signed confidentiality nondisclosure agreement will be required to receive copies of any patent application(s) that have not been published or issued by the United States Patent and Trademark Office of the World Intellectual Property Organization.

**SUPPLEMENTARY INFORMATION:** This invention concerns small molecule compounds that antagonize the activity of the thyroid stimulating hormone receptor ("TSHR"). These antagonists are classified into two functional categories: (a) Neutral antagonists that prevent TSHR from being turned on, and (b) inverse agonists that turn off active TSHR. Both categories of antagonists may be useful in treating hyperthyroidism and Graves' disease, an autoimmune disease that is commonly associated with hyperthyroidism. In addition, certain small molecule compounds that function as inverse agonists of TSHR may be effective in reducing the recurrence of thyroid cancer.

The prospective Start-Up Exclusive Patent License is being considered under the small business initiative launched on 1 October 2011 and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective Start-Up Exclusive Patent License may be granted unless the NIH receives written evidence and argument, within fifteen (15) days from the date of this published notice, that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

Complete applications for a license in the prospective field of use that are filed in response to this notice will be treated as objections to the grant of the contemplated Start-Up Exclusive Patent License. Comments and objections submitted to this notice will not be made available for public inspection and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.

Dated: May 20, 2013.

**Richard U. Rodriguez,**

Director, Division of Technology Development & Transfer, Office of Technology Transfer, National Institutes of Health.

[FR Doc. 2013-12375 Filed 5-23-13; 8:45 am]

**BILLING CODE 4140-01-P**